What is RxMapper?
RxMapper is a pioneering personalized medication platform and telehealth service, developed in collaboration with Mayo Clinic. The company leverages DNA analysis to tailor medication selection for individuals, aiming to optimize treatment efficacy and reduce healthcare expenditures. Its services are designed for a broad audience, including employees, employers, health plans, brokers, consultants, and pharmacists. By integrating genetic sequencing with telehealth consultations, RxMapper provides precise medication recommendations based on an individual's unique genetic profile, covering over 6,500 commercial drugs.
How much funding has RxMapper raised?
RxMapper has raised a total of $5.7M across 1 funding round:
Other Financing Round
$5.7M
Other Financing Round (2024): $5.7M, investors not publicly disclosed
What's next for RxMapper?
The substantial enterprise-level funding positions RxMapper for accelerated growth and market expansion. This strategic investment will likely fuel further development of its DNA-based personalized medication platform and telehealth services. Future initiatives may include broadening its service reach, enhancing its analytical capabilities, and forging new strategic partnerships within the healthcare ecosystem to solidify its role in improving patient outcomes and managing costs through precision medicine.
See full RxMapper company page
